Anthony D. Ho

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood

Wolfgang Wagner, Frederik Wein, Anja Seckinger et al. · Experimental Hematology · 2005 · 1.2K citations · Full text

Regenerative Medicine, Tissue Engineering, Developmental Biology +15

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

Hematological Malignancy, Lymphoid Neoplasia, Elderly Patients +7

Replicative Senescence of Mesenchymal Stem Cells: A Continuous and Organized Process

Wolfgang Wagner, Patrick Horn, M. Castoldi et al. · PLoS ONE · 2008 · 1.1K citations · Full text

Adult Stem Cell, Regenerative Medicine, Organized Process +17

Human haematopoietic stem cell lineage commitment is a continuous process

Lars Velten, Simon Haas, Simon Raffel et al. · Nature Cell Biology · 2017 · 906 citations · Full text

Developmental Biology, Medicine, Stem Cell Mobilization +7